Medical Pharmacology : Antiparkinson's Disease
Drug Practice Questions
Click on the correct answer.
An alternative to L-dopa for managing parkinsonism would be drugs that act as direct antagonists at striatal dopamine receptors.
True
False
Which one(s) of the following statements is/are correct concerning dopamine-receptor agonists?
Dopamine receptor agonists require enzymatic transformation to their active forms. As such, they are "prodrugs."
Dopamine receptor agonists, used clinically, must be administered more frequently than L-dopa because these receptor agonists have relatively short duration of action.
Both
Neither
Which one(s) of the following drugs are classified as dopamine receptor agonists and or frequently used for treatment of parkinsonism?
Pramipexole
Ropinirole
Both
Neither
This dopamine receptor has been associated with cardiac valve fibrosis and, as a consequence, has been withdrawn from the US market (2007).
Bromocriptine
Apomorphine
Pergolide
None of the above
Ropinirole or pramipexole administration may exhibit which one(s) of the following side effects?
Confusion
Nausea
Hypertension
A & B
A & C
B & C
A, B & C
This dopamine antagonist which can be administered by subcutaneous injection has been FDA approved as "rescue therapy" for acute intermittent management of "off" occurrences in patients exhibiting dopaminergic therapeutic response fluctuation.
Ropinerole
Apomorphine
Pergolide
Bromocryptine
Concurrent administration of apomorphine and ondansetron may result in which one(s) of the following adverse effect/effects?
Loss of consciousness
Significant hypotension
Both
Neither
COMT (catechol-o-methyltransferase) inhibitor/inhibitors available for managing Parkinson's disease:
Tolcapone
Entacapone
Both
Neither
Which one of the following agents (COMT inhibitors) has a relatively short duration of action?
Tolcapone
Entacapone
This COMT inhibitor is associated with an important adverse side effect, hepatotoxicity. Increased serum alanine aminotransferase and aspartate transaminase has been observed in up to about 2% of patients treated with this agent.
